medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2020-22-5-8medalphabet-1673Research ArticleСтатьиЛамотриджин в терапии хронических болевых синдромовLamotrigine in treatment of chronic pain syndromesЕкушеваЕ. В.EkushevaE. V.

Доктор медицинских наук, профессор, заведующая кафедрой нервных болезней

Москва, Белгород

Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» ФМБА России; Клиника головной боли и вегетативных расстройств им. академика А. Вейна; ФГАОУ ВО «Белгородский государственный национальный исследовательский университет»РоссияAcademy of Postgraduate Education of the Federal Research and Clinical Centre for Specialized Medical Care and Medical Technologies; Clinic for Headache and Autonomic Disorders n.a. Academician A. Wein; Belgorod National Research UniversityRussian Federation202019102020022Неврология и психиатрия (3)58Copyright © Екушева Е.В., 20202020Екушева Е.В.Ekusheva E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1673

Хронические болевые синдромы представляют значительную социально-экономическую проблему для здравоохранения и всего общества в целом в связи с недостаточным эффектом проводимого лечения, выраженным снижением качества жизни и значительной степенью дезадаптации этой категории пациентов. Далеко не всегда терапия хронических болевых синдромов препаратами первой линии из группы антиконвульсантов (габапентин, прегабалин, карбамазепин, вальпроевая кислота и топирамат) имеет ожидаемый эффект, нередко наблюдаются разнообразные побочные и нежелательные явления. Это предполагает поиск возможностей и перспектив применения в качестве инструментов фармакологического воздействия других антиконвульсантов нового поколения, одним из которых является ламотриджин. В статье рассматривается широкий спектр эффективного и безопасного использования Ламитора при разнообразных заболеваниях, сопровождающихся хронической болью.

Chronic pain syndromes represent a significant socio-economic problem for health care and society as a whole due to the insufficient effect of the treatment, a pronounced decrease in the quality of life and a significant degree of maladjustment of this category of patients. Treatment of chronic pain syndromes with first-line drugs from the group of anticonvulsants (gabapentin, pregabalin, carbamazepine, valproic acid and topiramate) does not always give the expected effect, and various side and undesirable effects are often observed. This implies the search for opportunities and prospects for the use of other new generation anticonvulsants, one of which is lamotrigine, as a means of pharmacological action. The article discusses a wide range of effective and safe use of Lamitor for various diseases accompanied by chronic pain.

хроническая больмигрень с ауройневропатическая больтригеминальная невралгияламотриджинЛамитор.chronic painmigraine with auraneuropathic paintrigeminal neuralgialamotrigineLamitorReferencesBorouierdi A., Zeng J., Sharp K. et al. Calcium channel 2-delta 1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. // Pain. N 152 (3). Р. 649–655.Borouierdi A., Zeng J., Sharp K. et al. Calcium channel 2-delta 1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. // Pain. N 152 (3). Р. 649–655.Titlic M., Lukir J., Tonkic A. et al. Lamotrigine in the treatment of the pain syndromes and neuropathic pain. // Bratislavske Lekarske Listy. 2008. N109 (9). Р. 421–424.Titlic M., Lukir J., Tonkic A. et al. Lamotrigine in the treatment of the pain syndromes and neuropathic pain. // Bratislavske Lekarske Listy. 2008. N109 (9). Р. 421–424.Kuzniecky R. Modulation of cerebral GABA by topiramate, lamotrigine and gabapentin in healthy adults. // Neurology. 2002. N58. P. 368–372.Kuzniecky R. Modulation of cerebral GABA by topiramate, lamotrigine and gabapentin in healthy adults. // Neurology. 2002. N58. P. 368–372.Lampl С., Katsarava Z., Diener H.-C., Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. // Journal of Neurology, Neurosurgery & Psychiatry. 2005. N76 (12). Р. 1730–1732.Lampl С., Katsarava Z., Diener H.-C., Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. // Journal of Neurology, Neurosurgery & Psychiatry. 2005. N76 (12). Р. 1730–1732.Zheng C., Yang K., Liu Q. et al. The anticonvulsive drug lamotrigine blocks neuronal{alpha}4{beta}2-nicotinic acetylcholine receptors. // The Journal of Pharmacology and Experimental Therapeutics. 2010. N335 (2). Р. 401–408.Zheng C., Yang K., Liu Q. et al. The anticonvulsive drug lamotrigine blocks neuronal{alpha}4{beta}2-nicotinic acetylcholine receptors. // The Journal of Pharmacology and Experimental Therapeutics. 2010. N335 (2). Р. 401–408.Yang R., Dunn J. F., Su D. et al. Lamotrigine inhibits TRESK regulated by G protein coupled receptor agonist. // The Journal of Neuroscience. 2018. N367. Р. 368–375.Yang R., Dunn J. F., Su D. et al. Lamotrigine inhibits TRESK regulated by G protein coupled receptor agonist. // The Journal of Neuroscience. 2018. N367. Р. 368–375.Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. // The Lancet Neurology. 2017. N390. Р. 1211–1859.Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. // The Lancet Neurology. 2017. N390. Р. 1211–1859.Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. // Cephalalgia. 2018. N38. P. 1–211.Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. // Cephalalgia. 2018. N38. P. 1–211.Buch D., Chabriat H. Lamotrigine in the prevention of migraine with aura: a narrative review. // Headache. 2019. N59 (8). Р. 1187–1197.Buch D., Chabriat H. Lamotrigine in the prevention of migraine with aura: a narrative review. // Headache. 2019. N59 (8). Р. 1187–1197.Cologno D., d’Onofrio F., Castriota O. et al. Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up. // Neurological Sciences. 2013. N34 (Suppl 1). Р. S 165–S 166.Cologno D., d’Onofrio F., Castriota O. et al. Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up. // Neurological Sciences. 2013. N34 (Suppl 1). Р. S 165–S 166.d'Onofrio F., Cologno D., Petretta V. et al. Basilar-type migraine responsive to lamotrigine: three case reports. // Neurological Sciences. 2007. N28 (Suppl 2). P. S 239–41.d'Onofrio F., Cologno D., Petretta V. et al. Basilar-type migraine responsive to lamotrigine: three case reports. // Neurological Sciences. 2007. N28 (Suppl 2). P. S 239–41.Viana M., Afridi S. Migraine with prolonged aura: phenotype and treatment. // Naunyn-Schmiedeberg's Archives of Pharmacology. 2018. N391 (1). Р. 1–7.Viana M., Afridi S. Migraine with prolonged aura: phenotype and treatment. // Naunyn-Schmiedeberg's Archives of Pharmacology. 2018. N391 (1). Р. 1–7.Pascual J., Caminero A. B., Mateos V. et al. Preventing disturbing migraine aura with lamotrigine: an open study. // Headache. 2004. N44 (10). Р. 1024–1028.Pascual J., Caminero A. B., Mateos V. et al. Preventing disturbing migraine aura with lamotrigine: an open study. // Headache. 2004. N44 (10). Р. 1024–1028.Pelzer N., Stam A.H., Carpay J.A. et al. Familial hemiplegic migraine treated by sodium valproate and lamotrigine. // Cephalalgia. 2014. N34. Р. 708–711.Pelzer N., Stam A.H., Carpay J.A. et al. Familial hemiplegic migraine treated by sodium valproate and lamotrigine. // Cephalalgia. 2014. N34. Р. 708–711.Camia F., Pisciotta L., Morana G. et al. Combined early treatment in hemiplegic attacks related to CACNA1A encephalopathy with brain oedema: Blocking the cascade? // Cephalalgia. 2017. N37. Р. 1202–1206.Camia F., Pisciotta L., Morana G. et al. Combined early treatment in hemiplegic attacks related to CACNA1A encephalopathy with brain oedema: Blocking the cascade? // Cephalalgia. 2017. N37. Р. 1202–1206.Liguori C., Albanese M., Sancesario G. et al. May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis. // Neurological Sciences. 2013. N34. Р. 1845–1846.Liguori C., Albanese M., Sancesario G. et al. May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis. // Neurological Sciences. 2013. N34. Р. 1845–1846.Thissen S., Vos I.G., Schreuder T.H. et al. Persistent migraine aura: New cases, a literature review, and ideas about pathophysiology. // Headache. 2014. N54. Р. 1290–1309.Thissen S., Vos I.G., Schreuder T.H. et al. Persistent migraine aura: New cases, a literature review, and ideas about pathophysiology. // Headache. 2014. N54. Р. 1290–1309.Bronstein A.M., Lempert T. Dizziness: a practical approach to diagnosis and management. // Cambridge University Press. 2007. P. 83–91.Bronstein A.M., Lempert T. Dizziness: a practical approach to diagnosis and management. // Cambridge University Press. 2007. P. 83–91.Dieterich M., Obermann M., Celebisoy N. Vestibular migraine: the most frequent entity of episodic vertigo. // Journal of Neurology. 2016. N263 (Suppl. 1). S 82–89.Dieterich M., Obermann M., Celebisoy N. Vestibular migraine: the most frequent entity of episodic vertigo. // Journal of Neurology. 2016. N263 (Suppl. 1). S 82–89.Bisdorff A.R. Treatment of migraine related vertigo with lamotrigine an observational study. // Bulletin of the Medical Science Society of the Grand Duchy of Luxembourg. 2004. N2. Р. 103–108.Bisdorff A.R. Treatment of migraine related vertigo with lamotrigine an observational study. // Bulletin of the Medical Science Society of the Grand Duchy of Luxembourg. 2004. N2. Р. 103–108.Zhang L., Wilson M., Yamagishi L. Lamotrigine as a prophylactic treatment for migraine-associated vertigo: A case series. // Neurology. 2014. N 82 (10 Suppl.). Poster 7.193.Zhang L., Wilson M., Yamagishi L. Lamotrigine as a prophylactic treatment for migraine-associated vertigo: A case series. // Neurology. 2014. N 82 (10 Suppl.). Poster 7.193.Chen W. T., Fuh J. L., Lu S.R., Wang S. J. Persistent migrainous visual phenomena might be responsive to lamotrigine. // Headache. 2001; 41: 823–825.Chen W. T., Fuh J. L., Lu S.R., Wang S. J. Persistent migrainous visual phenomena might be responsive to lamotrigine. // Headache. 2001; 41: 823–825.Schankin C. J., Maniyar F.H., Digre K. B., Goadsby P. J. “Visual snow” – A disorder distinct from persistent migraine aura. // Brain. 2014. N 137. Р. 1419–1428.Schankin C. J., Maniyar F.H., Digre K. B., Goadsby P. J. “Visual snow” – A disorder distinct from persistent migraine aura. // Brain. 2014. N 137. Р. 1419–1428.Traber G. L., Piccirellic M., Michels L. Visual snow syndrome: a review on diagnosis, pathophysiology, and treatment. // Current Opinion Neurology. 2020. N33 (1). P. 74–78.Traber G. L., Piccirellic M., Michels L. Visual snow syndrome: a review on diagnosis, pathophysiology, and treatment. // Current Opinion Neurology. 2020. N33 (1). P. 74–78.Bendtsen L., Zakrzewska J. M., Abbott J. et al. European Academy of Neurology guideline on trigeminal neuralgia. // European Journal of Neurology. 2019. N26 (6). Р. 831–849.Bendtsen L., Zakrzewska J. M., Abbott J. et al. European Academy of Neurology guideline on trigeminal neuralgia. // European Journal of Neurology. 2019. N26 (6). Р. 831–849.Gronseth G., Cruccu G., Alksne J. et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. // Neurology. 2008. N71 (15). Р. 1183–1190.Gronseth G., Cruccu G., Alksne J. et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. // Neurology. 2008. N71 (15). Р. 1183–1190.Alves T. C., Azevedo G. S., Carvalho E. S. [Pharmacological treatment of trigeminal neuralgia: systematic review and metanalysis] [in Portuguese]. // Brazilian Journal of Anesthesiology. 2004. N54. Р. 836–849.Alves T. C., Azevedo G. S., Carvalho E. S. [Pharmacological treatment of trigeminal neuralgia: systematic review and metanalysis] [in Portuguese]. // Brazilian Journal of Anesthesiology. 2004. N54. Р. 836–849.Al-Quliti K.W. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. // Neurosciences. 2015. N20 (2). Р. 107–114.Al-Quliti K.W. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. // Neurosciences. 2015. N20 (2). Р. 107–114.Kalita J., Chandra S., Misra U.K. Pregabalin and lamotrigine in central poststroke pain: A pilot study. // Neurology India. 2017. N65 (3). Р. 506–511.Kalita J., Chandra S., Misra U.K. Pregabalin and lamotrigine in central poststroke pain: A pilot study. // Neurology India. 2017. N65 (3). Р. 506–511.Finnerup N.B., Gottrup H, Jensen T. S. Anticonvulsants in central pain. // Expert Opinion Pharmacotherapy. 2002. N3 (10). Р. 1411–1420.Finnerup N.B., Gottrup H, Jensen T. S. Anticonvulsants in central pain. // Expert Opinion Pharmacotherapy. 2002. N3 (10). Р. 1411–1420.Vestergaard K., Andersen G., Gottrup H. et al. Lamotrigine for central poststroke pain: a randomized controlled trial. // Neurology. 2001. N56 (2). Р. 184–190.Vestergaard K., Andersen G., Gottrup H. et al. Lamotrigine for central poststroke pain: a randomized controlled trial. // Neurology. 2001. N56 (2). Р. 184–190.Frese А., Husstedt I. W., Ringelstein E. B., Evers S. Pharmacologic treatment of central poststroke pain. // Clinical Journal of Pain. 2006. N22 (3). Р. 252–60.Frese А., Husstedt I. W., Ringelstein E. B., Evers S. Pharmacologic treatment of central poststroke pain. // Clinical Journal of Pain. 2006. N22 (3). Р. 252–60.Eisenberg E., Lurie Y., Braker C. et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. // Neurology. 2001. N 57 (3). Р. 505–509.Eisenberg E., Lurie Y., Braker C. et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. // Neurology. 2001. N 57 (3). Р. 505–509.Singleton J. R., Smith A. G., Russel J. et al. Polyneuropathy with impaired glucose tolerance: implication for diagnosis and therapy. // Current Treat Options in Neurology. 2005. N7 (1). P. 33–42.Singleton J. R., Smith A. G., Russel J. et al. Polyneuropathy with impaired glucose tolerance: implication for diagnosis and therapy. // Current Treat Options in Neurology. 2005. N7 (1). P. 33–42.Vinic A. J., Tuchman M., Safirstein B. et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. // Pain. 2007. N128 (1–2). Р. 167–179.Vinic A. J., Tuchman M., Safirstein B. et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. // Pain. 2007. N128 (1–2). Р. 167–179.Chong M. S., Hester J. Diabetic painful neuropathy: current and future treatment options. // Drugs. 2007. N67 (4). Р. 569–585.Chong M. S., Hester J. Diabetic painful neuropathy: current and future treatment options. // Drugs. 2007. N67 (4). Р. 569–585.Simpson D.M., McArthur J.C., Olney R. et al. Lamotrigine HIV neuropathy study team. // Neurology. 2003. N60 (9). Р. 1508–1514.Simpson D.M., McArthur J.C., Olney R. et al. Lamotrigine HIV neuropathy study team. // Neurology. 2003. N60 (9). Р. 1508–1514.Finnerup N.B., Sindrup S.H., Bach F.W. et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. // Pain. 2002. N96 (3). Р. 375–383.Finnerup N.B., Sindrup S.H., Bach F.W. et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. // Pain. 2002. N96 (3). Р. 375–383.Cohen A. Trigeminal autonomic cephalalgias: a diagnostic and therapeutic overview. // ACNR. Headache series. 2014. N14 (4). Р. 12–15.Cohen A. Trigeminal autonomic cephalalgias: a diagnostic and therapeutic overview. // ACNR. Headache series. 2014. N14 (4). Р. 12–15.Lambru G., Matharu M. C. SUNCT and SUNA: medical and surgical treatment. // Neurological Sciences. 2013. N34 (Suppl. 1). Р. S 75–81.Lambru G., Matharu M. C. SUNCT and SUNA: medical and surgical treatment. // Neurological Sciences. 2013. N34 (Suppl. 1). Р. S 75–81.

The authors declare that there are no conflicts of interest present.